OA-18 Association of Cardiac Biomarkers and Adverse Events with a Carfilzomib-Containing Quadruplet in High-Risk Newly Diagnosed Multiple Myeloma Patients: Correlative Program of the GMMG-CONCEPT Trial

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01859-7

Lisa Leypoldt, Linlin Guo, Britta Besemer, Mathias Hänel, Marc-Steffen Raab, Christoph Mann, Christian S. Michel, Hans Christian Reinhardt, Igor Wolfgang Blau, Martin Görner, Yon-Dschun Ko, Maike de Wit, Hans Salwender, Christof Scheid, Ullrich Graeven, Rudolf Peceny, Peter Staib, Annette Dieing, Hartmut Goldschmidt, Carsten Bokemeyer, Antonia Beitzen-Heineke

引用次数: 0

查看原文本刊更多论文

OA-18 在高风险新诊断多发性骨髓瘤患者中使用含卡非佐米的四联疗法与心脏生物标志物和不良事件的关联：GMMG-CONCEPT试验的相关计划

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.